801
Participants
Start Date
February 8, 2024
Primary Completion Date
August 30, 2024
Study Completion Date
August 30, 2024
suspected asthma
enrollment 200 asthma patients
suspected COPD
enrollment 200 COPD patients
confirmed asthma
enrollment 200 patients
confirmed COPD
enrollment 200 patients
Research Site, Beijing
Research Site, Changsha
Research Site, Chengdu
Research Site, Chongqing
Research Site, Dalian
Research Site, Fengcheng
Research Site, Fuyang
Research Site, Fuzhou
Research Site, Guangzhou
Research Site, Guiyang
Research Site, Haikou
Research Site, Hanchuan
Research Site, Hangzhou
Research Site, Haozhou
Research Site, Henan
Research Site, Hong Kong
Research Site, Jinan
Research Site, Jingzhou
Research Site, Kunming
Research Site, Mianyang
Research Site, Nanchang
Research Site, Nantong
Research Site, Ningbo
Research Site, Ordos
Research Site, Panzhou
Research Site, Qionghai
Research Site, Shanghai
Research Site, Shenyang
Research Site, Shenzhen
Research Site, Suining
Research Site, Suzhou
Research Site, Taiyuan
Research Site, Taizhou
Research Site, Tianjin
Research Site, Xinyang
Research Site, Yulin
Research Site, Yunnan
Research Site, Zhaotong
Research Site, Zhengzhou
Research Site, Zhuji
Research Site, Zigong
Lead Sponsor
AstraZeneca
INDUSTRY